Recent Advances in Targeted Therapy in the Management of Chronic Lymphocytic Leukemia (CLL): A Closer Look at the Role of Emerging Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow and is the most common type of leukemia in adults. It affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. Patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Furthermore, patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. After chronic lymphocytic leukemia has been diagnosed, tests are done to find out how far the cancer has spread in the blood and bone marrow. While generally considered incurable, CLL progresses slowly in most cases. CLL treatment focuses on controlling the disease and its symptoms. Initial CLL treatments vary depending on the exact diagnosis and the progression of the disease. Fortunately, clinicians have recently been equipped with more options, including targeted therapies, which individualize therapy for patients with CLL, ultimately improving patient outcomes. Additionally, there are newer targeted options, including PI3K inhibitors, that have shown great promise in late stage clinical trials, especially in patients who have progressed on previous therapy. These new options have shown improved efficacy and safety in CLL.

Upon completion of this activity, participants will be able to:

  • Analyze the latest clinical evidence surrounding current and emerging targeted therapies for CLL, distinguishing among mechanism of action, efficacy in distinct patient populations, adverse event profiles, and long-term data

  • Explore the evolving role of current and next generation BTK inhibitors in the management of CLL

  • Examine the role of oral therapies in the management of CLL patients with or without a 17p deletion

  • Assess ways to incorporate the new and emerging CLL treatment options into the current paradigm of care for patients with CLL, including the management of complications related to resistance, relapse, and treatment-related adverse events

  • Examine the managed care considerations of current and emerging BTK inhibitors by exploring where these agents fit in the evolving CLL treatment paradigm

  • Discuss strategies to mitigate and manage predictable toxicities that have been reported with the use of targeted therapies in CLL, including BTK inhibitors

Faculty: Matthew S. Davids, MD, MMSc
Assistant Professor of Medicine
Harvard Medical School
Associate Director, CLL Center
Dana-Farber Cancer Institute


Dr. Davids serves on an advisory board for AbbVie, Acerta Pharma, Adaptive Biotechnologies, Genentech, Janssen, and TG Therapeutics. He serves as a consultant for AbbVie, Genentech, Janssen, MEI Pharma, Syros, and Verastem. He has received grant/research support from Acerta, Ascentage, Genentech, MEI, Surface Oncology, TG Therapeutics, and Verastem. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue